Treatment history of patients receiving biologic therapy for psoriasis - a Danish nationwide study

Abstract

Psoriasis is a common skin disease affecting approximately 2-4% of the world's population.[1] Management of psoriasis often involves prolonged treatment with topical-, systemic-, and biologic agents. Topical agents, i.e. topical corticosteroids or topical vitamin D analogues, are considered first-line of treatment for psoriasis, whereas biologics are predominantly used as a last resort, often as the result of treatment failure of conventional systemic agents. However, the specific treatment algorithms may differ between patients and countries, and certain therapies may be used off-label.

This article is protected by copyright. All rights reserved.

http://ift.tt/2kBDwFv